MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$250,000
Net Income
$388,147
Net Profit Margin
155.26%
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Service revenue
250,000
-
-
-
Research and development
345
795
3,272.5*
426
General and administrative
1,093,220
1,852,590
2,347,913.5*
490,547
Total operating expenses
1,093,565
1,853,385
2,351,186
490,973
Loss from operations
-843,565
-1,853,385
-2,351,186*
-490,973
Gain on derecognition of non-financial asset
1,100,000
-
-
-
Change in fair value of investment in gmp bio
-
-
281,653,161.25*
-
Change in fair value equity investment
300,000
-
-
-
Interest expense, net
318,292
295,811
191,474*
231,338
Change in fair value of derivative on debt
102,868
-90,080
215,362*
-392,058
Loss on debt conversion
-
-
-1,058,976*
-
Miscellaneous income
-
-
1,407.75*
-
Total other income
1,184,576
-385,891
280,619,481*
-623,396
Net income (loss) before income taxes
-
-
278,268,295*
-
Provision for income taxes
-
-
27,887,500*
-
Net income (loss) before non-controlling interests
341,011
-2,239,276
250,380,795*
-1,114,369
Net loss attributable to non-controlling interests
-47,136
-45,500
-53,300.5*
-67,004
Net income (loss) attributable to oncotelic therapeutics, inc
388,147
-2,193,776
250,434,095.5
-1,047,365
Basic EPS
0
0
0.585
0
Diluted EPS
0
0
0.639
-
Basic Average Shares
447,386,505
443,801,416
428,408,639
426,435,213
Diluted Average Shares
467,914,165
443,801,416
391,660,436
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Gain on
derecognition of...
$1,100,000
Change in fair value
equity investment
$300,000
Change in fair value of
derivative on debt
$102,868
(-78.75%↓ Y/Y)
Total other income
$1,184,576
(328.55%↑ Y/Y)
Interest expense, net
$318,292
(53.19%↑ Y/Y)
Net income (loss)
before...
$341,011
(62.04%↑ Y/Y)
Net loss
attributable to...
-$47,136
(30.07%↑ Y/Y)
Loss from operations
-$843,565
(-1178.73%↓ Y/Y)
Service revenue
$250,000
Net income (loss)
attributable to oncotelic...
$388,147
(39.69%↑ Y/Y)
Total operating
expenses
$1,093,565
(1557.70%↑ Y/Y)
General and
administrative
$1,093,220
(1564.67%↑ Y/Y)
Research and development
$345
(16.16%↑ Y/Y)
Buy us a coffee
Oncotelic Therapeutics, Inc. (OTLC)
Oncotelic Therapeutics, Inc. (OTLC)